Skip to content
  • About us
    • Our DNA
    • Board members
    • Our leadership
    • Partners
  • Pipeline
    • VTX-801 – Wilson’s disease
    • > VTX-801 in Wilson disease – GATEWAY – Phase 1/2 Clinical Trial
    • VTX-802 & VTX-803 – PFIC
    • VTX-804 – Citrullinemia Type 1
    • VTX–806 – Cerebrotendinous Xanthomatosis
  • Investors
  • News
  • Events
  • Patients & Families
    • Patient’s Stories
    • Patient advocacy
    • Patient & Families ressources
    • Compassionate Use and Expanded Access
  • Work at Vivet
Menu
  • About us
    • Our DNA
    • Board members
    • Our leadership
    • Partners
  • Pipeline
    • VTX-801 – Wilson’s disease
    • > VTX-801 in Wilson disease – GATEWAY – Phase 1/2 Clinical Trial
    • VTX-802 & VTX-803 – PFIC
    • VTX-804 – Citrullinemia Type 1
    • VTX–806 – Cerebrotendinous Xanthomatosis
  • Investors
  • News
  • Events
  • Patients & Families
    • Patient’s Stories
    • Patient advocacy
    • Patient & Families ressources
    • Compassionate Use and Expanded Access
  • Work at Vivet

Pipeline

Twitter Linkedin
About us
  • Our DNA
  • Board members
  • Our leadership
  • Partners
  • Our DNA
  • Board members
  • Our leadership
  • Partners
Pipeline
  • VTX-801 – Wilson’s disease
  • > VTX-801 in Wilson disease – GATEWAY
  • VTX-802 & VTX-803 – PFIC
  • VTX-804 – Citrullinemia Type 1
  • VTX – 806 – Cerebrotendinous Xanthomatosis
  • VTX-801 – Wilson’s disease
  • > VTX-801 in Wilson disease – GATEWAY
  • VTX-802 & VTX-803 – PFIC
  • VTX-804 – Citrullinemia Type 1
  • VTX – 806 – Cerebrotendinous Xanthomatosis
Patients & Families
  • Patient stories
  • Patient advocacy
  • Patient & Families ressources
  • Compassionate Use and Expanded Access
  • Patient stories
  • Patient advocacy
  • Patient & Families ressources
  • Compassionate Use and Expanded Access
  • News
  • Events
  • Investors
  • Work at Vivet
  • Contact
  • News
  • Events
  • Investors
  • Work at Vivet
  • Contact

Vivet Therapeutics Cookie Policy